Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia

Leukemia. 2018 Oct;32(10):2278-2281. doi: 10.1038/s41375-018-0059-3. Epub 2018 Feb 20.

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].

PMID: 29479067
DOI: 10.1038/s41375-018-0059-3

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use*
Female
Humans
Lenalidomide / adverse effects*
Lenalidomide / therapeutic use*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Middle Aged

Substances

Antineoplastic Agents
Lenalidomide